238 related articles for article (PubMed ID: 29111036)
1. GABA
Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
[TBL] [Abstract][Full Text] [Related]
2. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
[TBL] [Abstract][Full Text] [Related]
3. Ternary polymeric nanoparticles for oral siRNA delivery.
Zhang J; He C; Tang C; Yin C
Pharm Res; 2013 May; 30(5):1228-39. PubMed ID: 23307349
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
5. Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers.
Raja MA; Katas H; Jing Wen T
PLoS One; 2015; 10(6):e0128963. PubMed ID: 26068222
[TBL] [Abstract][Full Text] [Related]
6. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.
Liu X; Howard KA; Dong M; Andersen MØ; Rahbek UL; Johnsen MG; Hansen OC; Besenbacher F; Kjems J
Biomaterials; 2007 Feb; 28(6):1280-8. PubMed ID: 17126901
[TBL] [Abstract][Full Text] [Related]
7. Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.
Unsoy G; Gunduz U
Expert Rev Anticancer Ther; 2016 Jul; 16(7):789-97. PubMed ID: 27130312
[TBL] [Abstract][Full Text] [Related]
8. Development and characterisation of chitosan nanoparticles for siRNA delivery.
Katas H; Alpar HO
J Control Release; 2006 Oct; 115(2):216-25. PubMed ID: 16959358
[TBL] [Abstract][Full Text] [Related]
9. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.
Akbaba H; Erel-Akbaba G; Kotmakçı M; Başpınar Y
Pharm Res; 2020 Aug; 37(8):165. PubMed ID: 32761250
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
12. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
[TBL] [Abstract][Full Text] [Related]
13. Preparation and biological activity studies of resveratrol loaded ionically cross-linked chitosan-TPP nanoparticles.
Wu J; Wang Y; Yang H; Liu X; Lu Z
Carbohydr Polym; 2017 Nov; 175():170-177. PubMed ID: 28917853
[TBL] [Abstract][Full Text] [Related]
14. Development and Characterization of Gefitinib Loaded Polymeric Nanoparticles by Ionic Gelation Method.
Gupta M; Marwaha RK; Dureja H
Pharm Nanotechnol; 2017; 5(4):301-309. PubMed ID: 28982345
[TBL] [Abstract][Full Text] [Related]
15. Mannose-anchored N,N,N-trimethyl chitosan nanoparticles for pulmonary administration of etofylline.
Pardeshi CV; Agnihotri VV; Patil KY; Pardeshi SR; Surana SJ
Int J Biol Macromol; 2020 Dec; 165(Pt A):445-459. PubMed ID: 32987078
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
17. Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use.
Asasutjarit R; Theerachayanan T; Kewsuwan P; Veeranodha S; Fuongfuchat A; Ritthidej GC
AAPS PharmSciTech; 2015 Oct; 16(5):1013-24. PubMed ID: 25609376
[TBL] [Abstract][Full Text] [Related]
18. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
20. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages.
Zhang J; Tang C; Yin C
Biomaterials; 2013 May; 34(14):3667-77. PubMed ID: 23419643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
